LGD-4033 (Ligandrol) vs S-23

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

LGD-4033 (Ligandrol)S-23
CategorySARMsSARMs
Standard DoseResearch indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day.Research indicates 10-25 mg daily orally for 8-12 weeks. No human clinical trials — dosing extrapolated from rat pharmacology and anecdotal reports.
TimingOnce daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements.Split into 2 daily doses due to relatively short half-life (~12 hours). Morning and evening dosing.
Cycle Duration8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles.8 week cycles maximum recommended. PCT is absolutely mandatory due to profound HPG suppression. Allow full recovery before considering subsequent cycles.
Evidence Levelmoderate_humananimal_plus_anecdotal

Mechanism

LGD-4033 is a potent nonsteroidal selective androgen receptor modulator with high AR binding affinity (Ki of approximately 1 nM). It demonstrates strong anabolic activity in muscle and bone with significantly reduced androgenic activity in prostate tissue, achieving an anabolic-to-androgenic ratio of approximately 10:1. LGD-4033 activates the AR with full agonist efficacy in muscle, upregulating the PI3K/Akt/mTOR pathway for protein synthesis and satellite cell recruitment. It produces dose-dependent suppression of SHBG, total testosterone, LH, and FSH, indicating significant HPG axis suppression even at low doses.

Standard Dosing

Research indicates 5-10 mg daily orally for 8-12 weeks. Phase 1 data showed significant lean mass gains at 1 mg/day.

Timing

Once daily, consistent timing. Half-life approximately 24-36 hours. No food timing requirements.

Cycle Duration

8-12 week cycles maximum. PCT strongly recommended after all but the shortest/lowest-dose cycles.

Side Effects

  • Significant testosterone suppression (dose-dependent; occurs even at 1 mg/day)
  • Suppressed SHBG, LH, and FSH
  • Elevated liver enzymes / hepatotoxicity (case reports of cholestatic liver injury)
  • HDL cholesterol suppression
  • Headache
  • Fatigue (late-cycle, from suppression)
  • Water retention

Contraindications

  • Androgen-sensitive cancers
  • Pre-existing liver disease or elevated liver enzymes
  • Pregnancy and breastfeeding
  • Individuals under 21
  • Athletes subject to WADA/anti-doping testing

Best Stacking Partners

Cardarine GW-501516 (endurance without additional suppression)MK-677 (GH secretagogue for recovery)NAC / TUDCA (liver protection)
B

S-23

SARMs

Mechanism

S-23 is one of the most potent nonsteroidal SARMs developed, originally investigated by GTx, Inc. as a potential male hormonal contraceptive. It binds the androgen receptor with very high affinity, producing near-steroidal anabolic effects in muscle and bone while profoundly suppressing FSH and LH, leading to oligospermia and azoospermia in animal models. S-23 increases lean body mass and bone mineral density while reducing fat mass in a dose-dependent manner. The contraceptive effect was fully reversible in rat studies — spermatogenesis and fertility recovered completely after a 100-day washout period.

Standard Dosing

Research indicates 10-25 mg daily orally for 8-12 weeks. No human clinical trials — dosing extrapolated from rat pharmacology and anecdotal reports.

Timing

Split into 2 daily doses due to relatively short half-life (~12 hours). Morning and evening dosing.

Cycle Duration

8 week cycles maximum recommended. PCT is absolutely mandatory due to profound HPG suppression. Allow full recovery before considering subsequent cycles.

Side Effects

  • Profound testosterone suppression (near-complete LH/FSH shutdown)
  • Temporary infertility / azoospermia
  • Aggression and mood changes (reported frequently)
  • Hair loss (strong androgenic binding)
  • Testicular atrophy
  • Night sweats
  • Prostate effects (despite selectivity claims, S-23 had some prostate stimulation in rats)
  • HDL suppression

Contraindications

  • Desire for fertility in the near term (profound spermatogenic suppression)
  • Pre-existing liver disease
  • Androgen-sensitive cancers
  • Cardiovascular disease
  • Pregnancy and breastfeeding
  • Individuals under 21

Best Stacking Partners

hCG (to maintain testicular function during the profound suppression)MK-677 (non-suppressive GH elevation)NAC / TUDCA (liver support)Enclomiphene (PCT)

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →